Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Northland Capital Markets analyst Carl Byrnes downgrades Flexion Therapeutics (NASDAQ:FLXN) from Outperform to Market Perform.
Analysts have provided the following ratings for Flexion Therapeutics (NASDAQ:FLXN) within the last quarter:
Upgrades
HC Wainwright & Co. analyst Patrick Trucchio downgrades Flexion Therapeutics (NASDAQ:FLXN) from Buy to Neutral and lower...
Over the past 3 months, 4 analysts have published their opinion on Flexion Therapeutics (NASDAQ:FLXN) stock. These analysts ar...
Upgrades
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitti...
Evercore ISI Group raised Lear Corporation (NYSE: LEA) price target from $170 to $220. Lear shares fell 0.3% to close at $...
